非选择性beta受体阻滞剂治疗肝硬化门脉高压症患者研究进展*

doi:10.3969/j.issn.1672-5069.2022.01.036

Abstract

Abstract: Objective The liver cirrhosis (LC) is the consequence of various chronic liver diseases, with liver function abnormality and portal hypertension occurring in the decompensatory stage. The non-selective beta-blockers (NSBB) has been one of the main medicine for patients with portal hypertension in almost 3 decades, inasmuch as its capacity in reducing portal pressure, though, at the same time, the hemodynamic effects of NSBB can influence the circulatory function of patients. When and how to prescribe NSBB depends on patients' conditions. We aimed to review the reasonable application and controversy of NSBB treatment in cirrhotic patients.

Key words: Liver cirrhosis, Portal hypertension, Non-selective beta-blockers, Adrenergic beta-antagonists

Wu Ling, Li Feng. Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension[J]. Journal of Practical Hepatology, 2022, 25(1): 144-147.

References

[1] James SL, Abate D, Abate KH, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet,2018,392(10159):1789-1858.
[2] D'Amico G, Morabito A, D'Amico M, et al. Clinical states of cirrhosis and competing risks. J Hepatol,2018,68(3):563-576.
[3] Gracia-Sancho J, Marrone G, Fernandez-Iglesias A. Hepatic microcirculation and mechanisms of portal hypertension. Nat Rev Gastroenterol Hepatol,2019,16(4):221-234.
[4] Fernandez M. Molecular pathophysiology of portal hypertension. Hepatology.2015,61(4):1406-1415.
[5] Villanueva C, Albillos A, Genesca J, et al. Beta blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet,2019,393(10181):1597-1608.
[6] Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet,2014,383(9930):1749-1761.
[7] McConnell M, Iwakiri Y. Biology of portal hypertension. Hepatol Int,2018,12(Suppl 1):11-23.
[8] Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: A new view of an old problem. Clin Gastroenterol Hepatol,2015,13(12):2109-2117.
[9] Aller MA, Arias N, Blanco-Rivero J, et al. Hepatic encephalopathy: Sometimes more portal than hepatic. J Gastroenterol Hepatol,2019,34(3):490-494.
[10] Angeli P, Garcia-Tsao G, Nadim MK, et al. News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document. J Hepatol,2019,71(4):811-822.
[11] Simonetto DA, Liu M, Kamath PS. Portal hypertension and related complications: Diagnosis and management. Mayo Clin Proc,2019,94(4):714-726.
[12] Baffy G. Potential mechanisms linking gut microbiota and portal hypertension. Liver Int,2019,39(4):598-609.
[13] Bernardi M, Caraceni P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol,2018,15(12):753-764.
[14] Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: Variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Dig Dis,2016,34(4):382-386.
[15] Mehta G, Gustot T, Mookerjee RP, et al. Inflammation and portal hypertension - the undiscovered country. J Hepatol,2014,61(1):155-163.
[16] Moller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int,2018,38(4):570-580.
[17] Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med,2010,362(9):823-832.
[18] de Franchis R, Baveno VIF. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol,2015,63(3):743-752.
[19] Villanueva C, Albillos A, Genesca J, et al. Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension. Hepatology,2016,63(1):197-206.
[20] Reiberger T, Mandorfer M. Beta adrenergic blockade and decompensated cirrhosis. J Hepatol,2017,66(4):849-859.
[21] Vorobioff JD, Groszmann RJ. Prevention of portal hypertension: from variceal development to clinical decompensation. Hepatology,2015,61(1):375-381.
[22] Reiberger T, Ferlitsch A, Payer BA, et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J Hepatol,2013,58(5):911-921.
[23] Giannelli V, Lattanzi B, Thalheimer U, et al. Beta-blockers in liver cirrhosis. Ann Gastroenterol,2014,27(1):20-26.
[24] Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut,2016,65(8):1393-1394.
[25] Zacharias AP, Jeyaraj R, Hobolth L, et al. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev,2018,10:1-60.
[26] Tripathi D, Stanley AJ, Hayes PC, et al. U.K. guidelines on the management of variceal haemorrhage in cirrhotic patients. Gut,2015,64(11):1680-1704.
[27] Ge PS, Runyon BA. Treatment of patients with cirrhosis. N Engl J Med,2016,375(8):767-777.
[28] Bhutta AQ, Garcia-Tsao G, Reddy KR, et al. Beta-blockers in hospitalised patients with cirrhosis and ascites: mortality and factors determining discontinuation and reinitiation. Aliment Pharmacol Ther,2018,47(1):78-85.
[29] Giannelli V, Roux O, Laouenan C, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol,2020,72(3):463-471.
[30] Kimer N, Feineis M, Moller S, et al. Beta-blockers in cirrhosis and refractory ascites: a retrospective cohort study and review of the literature. Scand J Gastroenterol,2015,50(2):129-137.
[31] Leithead JA, Rajoriya N, Tehami N, et al. Non-selective beta-blockers are associated with improved survival in patients with ascites listed for liver transplantation. Gut,2015,64(7):1111-1119.
[32] Mookerjee RP, Pavesi M, Thomsen KL, et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J Hepatol,2016,64(3):574-582.
[33] Mandorfer M, Bota S, Schwabl P, et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology,2014,146(7):1680-1690.
[34] Gao YH, Wang JY, Liu PY, et al. Iron metabolism disorders in patients with hepatitis B-related liver diseases. World J Clin Cases, 2018,6(13):600-610.
[35] Lee NCW, Carella MA, Papa S, et al. High expression of glycolytic genes in cirrhosis correlates with the risk of developing liver cancer. Front Cell Dev Biol, 2018,6:138.
[36] Gimenez P, Garcia-Martinez I, Frances R, et al. Treatment with non-selective beta-blockers affects the systemic inflammatory response to bacterial DNA in patients with cirrhosis. Liver Int,2018,38(12):2219-2227.
[37] Madsen BS, Nielsen KF, Fialla AD, et al. Keep the sick from harm in spontaneous bacterial peritonitis: Dose of beta blockers matters. J Hepatol,2016,64(6):1455-1456.
[38] Kim HY, Cho EJ, Chun S, et al. Red blood cell alloimmunization in Korean patients with myelodysplastic syndrome and liver cirrhosis. Ann Lab Med, 2019,39(2):218-222.
[39] Fortea JI, Puente Á, Ruiz P, et al. Impact of an acute hemodynamic response-guided protocol for primary prophylaxis of variceal bleeding. World J Clin Cases, 2018,6(13):611-623.
[40] Khatri A, Kanaparthy NS, Selvaraj BJ, et al. Primary Klebsiella pneumoniae osteomyelitis with bacteremia and sepsis in a patient with cirrhosis. Case Rep Infect Dis, 2018,2018:3183805.
[41] De Gottardi A, Rautou PE, Schouten J, et al. Porto-sinusoidal vascular disease: proposal and description of a novel entity. Lancet Gastroenterol Hepatol, 2019,4(5):399-411.
[42] Nagai H, Mukozu T, Kobayashi K, et al. Influence of sorafenib on host immunity in patients with liver cirrhosis with advanced hepatocellular carcinoma stratified by etiology.Anticancer Res, 2019,39(4):2183-2191.
[43] Krag A, Wiest R, Albillos A, et al. The window hypothesis: haemodynamic and non-haemodynamic effects of beta-blockers improve survival of patients with cirrhosis during a window in the disease. Gut,2012,61(7):967-969.
[44] Ferrarese A, Tsochatzis E, Burroughs AK, et al. Beta-blockers in cirrhosis: therapeutic window or an aspirin for all? J Hepatol,2014,61(2):449-450.
[45] Garcia-Tsao G. Beta blockers in cirrhosis: The window re-opens. J Hepatol,2016,64(3):532-534.

Administration of non-selective beta-blockers in treatment of patients with liver cirrhosis and portal hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zeng Yi, Li Guo, Li Hongcui, et al. Efficacy of ursodeoxycholic acid in the treatment of patients with primary biliary cholangitis and cirrhosis and its effect on serum Nrf2 and HO-1 levels [J]. Journal of Practical Hepatology, 2022, 25(2): 211-214.
[2]	Hao Yuting, Lin Jie, Qin Jie. Clinical implication of serum aquaporin-8 and aquaporin-9 in patients with hepatitis B-induced liver cirrhosis receiving long-term entecavir therapy [J]. Journal of Practical Hepatology, 2022, 25(2): 243-246.
[3]	Wang Benxian, Li Wei, Li Dongsheng, et al. Cell-free and concentrated ascites reinfusion therapy for patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2022, 25(2): 247-250.
[4]	He Fuliang, Ma Lin, Li Yuerong, et al. Non-cirrhotic portal hypertension:the highlight of its diagnosis [J]. Journal of Practical Hepatology, 2022, 25(1): 1-4.
[5]	Zhang Yu, Liu Fuquan. Precision technique and rational shunt in transjugular intrahepatic portosystemic shunt [J]. Journal of Practical Hepatology, 2022, 25(1): 5-8.
[6]	Chen Jing, Zhu Yueyong. Non-invasive diagnosis of portal hypertension in patients with liver cirrhosis: serum markers or imaging? [J]. Journal of Practical Hepatology, 2022, 25(1): 9-12.
[7]	Li Yanle, Liu Xiaoyu, Yao Jianning, et al. Serum ammonia level changes and its correlation to cognitive impairment in patients with hepatitis B cirrhosis and hepatic encephalopathy [J]. Journal of Practical Hepatology, 2022, 25(1): 74-78.
[8]	Wang Jing, Bi Ning, Fang Liang, et al. Correlation of blood CD64 index to intestinal mucosal barrier functions in patients with hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2022, 25(1): 79-82.
[9]	Shi Cuicui, Liu Yanjun, Zhang Ruinan, et al. Dyslipidemia in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 859-862.
[10]	Liu Mei, Shi Yonghong, Ying Juan, et al. Prevalence of nosocomial infection and resistance of pathogens in patients with decompensated liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 863-866.
[11]	Liu Yuling, Zhen Zengguo, Wang Huijuan, et al. Effects of probiotics on intestinal barrier function of patients with liver cirrhosis complicated by spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2021, 24(6): 867-870.
[12]	Xing Li, Du Qianying, Jiang Yanli, et al. Impact of segmented injection of contrast agent on hepatic vein imaging by CT angiography in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 871-874.
[13]	Huang Liou, Wu Chunrong, Xu Dan, et al. Efficacy of continuous renal replacement therapy without heparinization in patients with liver cirrhosis complicated by hepatic encephalopathy [J]. Journal of Practical Hepatology, 2021, 24(6): 875-878.
[14]	Ye Dong, Zhang Junxia, LiJie, et al. Risk factors of rebleeding in hepatitis B liver cirrhotics with esophageal varices bleeding after endoscopic variceal ligation [J]. Journal of Practical Hepatology, 2021, 24(6): 879-882.
[15]	Han Chengmei, Han Yongfeng, Wang Chunhua. Risk factors for acute kidney injury in patients with hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2021, 24(6): 883-886.